With the onset of the pandemic, the increased use of telemedicine has been the biggest change to how cancer care is being delivered; however, whether telemedicine is here to stay depends on the regulators and payers, said Amy Ellis, chief quality officer at Northwest Medical Specialties.
With the onset of the pandemic, the increased use of telemedicine has been the biggest change to how cancer care is being delivered; however, whether telemedicine is here to stay depends on the regulators and payers, said Amy Ellis, chief quality officer at Northwest Medical Specialties.
Transcript
How has Northwest Medical Specialties altered how it delivers care to its patients with cancer during the pandemic?
I'd say the biggest thing is telemedicine. At one point, we had about 60% of our office visits were done on telemedicine. Now, there's a little bit of a difference between providers. We've got, you know, one provider who hit that 60% mark, and then we've got others that were around 30%, 40%. But I would say that was the biggest change of our care delivery is operationalizing, telemedicine.
We used 3 different tools before we finally settled on using Zoom Health. We had a pilot with our medical director, Dr. [Sibel] Blau, and she tried, I want to say she tried 6 different tools. So, she was very, very helpful when we were trying to really settle on what tool to use, because in order to really have that buy-in from the staff and patients, the tool that you use and select is so important. If you're having audio issues, video issues, either the provider is not going to be happy and they're not going to want to do telemedicine visits, or the patients aren't going to be happy and they're not going to understand how to get themselves on the screen. So, I would say telemedicine is probably the biggest change that we made in our care delivery.
How much do you expect changes, like telemedicine, to stay around once the pandemic resolves? Is that part of the future of the practice or will it go away?
I think it depends on the regulatory side of it. And we would hope that payers, Medicare, will continue paying for telemedicine in the way that they are. But of course, our delivery of care is often dependent on the reimbursement. So, I think that the jury's probably still out on that. We know that in some fashion, if you know all the sudden post-pandemic, they take away the reimbursement for the services, we'll still use it for several different things, whether that be nurse check-ins,or other visits that prior to the pandemic weren't really reimbursable.But I think truly, truly, it's going to depend on really what it looks like on the regulatory and the payer side of it.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Survey Finds Slow Start on CMS Interoperability Rule Implementation
April 10th 2025With deadlines looming in 2026 and 2027 for compliance with the CMS Advancing Interoperability and Improving Prior Authorization Final Rule, a survey indicates a concerning lack of readiness among payers and providers to meet the new requirements for data sharing.
Read More